A
A. von Heydebreck
Researcher at Merck KGaA
Publications - 9
Citations - 361
A. von Heydebreck is an academic researcher from Merck KGaA. The author has contributed to research in topics: Cetuximab & Irinotecan. The author has an hindex of 4, co-authored 9 publications receiving 355 citations.
Papers
More filters
Proceedings ArticleDOI
Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial
Luc Dirix,István Takács,Petros Nikolinakos,Guy Jerusalem,H.-T. Arkenau,Erika Hamilton,A. von Heydebreck,H-J Grote,Kevin M. Chin,Marc E. Lippman +9 more
TL;DR: Clinical activity of avelumab is reported in a cohort of patients (pts) with locally advanced (LA) or metastatic breast cancer (MBC) refractory to or progressing after standard-of-care therapy (NCT01772004).
Journal ArticleDOI
An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications.
Bastian Gunawan,A. von Heydebreck,Björn Sander,H‐J Schulten,Florian Haller,Claus Langer,Thomas Armbrust,M. Bollmann,Slavko Gašparov,D. Kovac,László Füzesi +10 more
TL;DR: In insights into the cytogenetic evolution obtained from oncogenetic tree models may eventually help to gain a better understanding of the heterogeneous site‐dependent biological behaviour of GISTs.
Journal ArticleDOI
Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data)
S. Tejpar,Marc Peeters,Yves Humblet,Jan B. Vermorken,G. De Hertogh,W. De Roock,Johannes Nippgen,A. von Heydebreck,C. Stroh,E. Van Cutsem +9 more
TL;DR: This work has shown that in pts with mCRC after failure of irinotecan-based therapy, the efficacy could be improved by escalating the dose of cetuximab, and this work aims to demonstrate this in patients with a prior history of central giant cell granuloma.
Journal ArticleDOI
Loss of 9p leads to p16INK4A down-regulation and enables RB/E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs).
Florian Haller,Christian Löbke,Markus Ruschhaupt,Markus Ruschhaupt,Silke Cameron,Hans-Juergen Schulten,S. Schwager,A. von Heydebreck,Bastian Gunawan,Claus Langer,Giuliano Ramadori,Holger Sültmann,Annemarie Poustka,Ulrike Korf,László Füzesi +14 more
TL;DR: It is concluded that loss of 9p accompanied by early G1 phase inhibitor p16INK4A down‐regulation in GISTs facilitates phosphorylation of RB, enabling E2F1‐dependent transcription of genes essential for late G1/S phase transition.
Journal ArticleDOI
913PAvelumab in patients with metastatic adrenocortical carcinoma (mACC): Results from the JAVELIN solid tumor trial
C. Le Tourneau,Corrine Zarwan,Christopher J. Hoimes,Deborah Jean Lee Wong,Sebastian Bauer,Martin Wermke,Hans Juergen Grote,A. von Heydebreck,Kevin M. Chin,J.L. Gulley +9 more
TL;DR: This work presents a meta-analyses of the immune-oncology and oncology of central giant cell granuloma, which has shown promise as a biomarker of disease progression in women and shows the potential for use in personalized medicine.